As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Glioblastoma Drug Treatment Study
This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.
In order to participate you must meet the following criteria:
- Have a newly diagnosed glioblastoma or gliosarcoma.
- Have completed temozolomide (TMZ) therapy with radiation.
- Have had no chemotherapy, immunotherapy, or radiation therapy other than temozolomide (TMZ) therapy with radiation.
- Are at least 18 years of age.
This is a partial list of elgibility requirements.